This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
28 Apr 2014

The US Biopharmaceutical Industry: Perspectives on Future Growth and the Factors that will Drive it

The Pharmaceutical Research and Manufacturers Association has published an industry report — "The US Biopharmaceutical Industry: Perspectives on Future Growth and the Factors that will Drive it".

 

Key findings of the report include

• As the ability to innovate is increasingly becoming the most important determinant of a nation’s future potential for economic growth and global competitiveness, the biopharmaceutical industry ranks among the most innovative advanced manufacturing industries in the US economy.

• Although the US is currently the world leader in innovative biopharmaceutical R&D and manufacturing, industry executives expressed concern that US leadership cannot be taken for granted.

•  The three policy factors identified as most critical for enabling innovation and the resulting economic contributions in biopharmaceutical R&D and manufacturing are (1) coverage and payment policies that support and encourage medical innovation; (2) a well-functioning, science-based regulatory system; and (3) strong IP protections.

• Insights from industry executives informed the development of two potential growth trajectories for the innovative biopharmaceutical industry in the US during the next 10 years, with well over 300,000 retained and newly created jobs at stake between the two scenarios. The industry executives viewed the likelihood of achieving these alternative futures as highly dependent on policy choices made in the US. 

 

To download a free copy of the report, click here.

 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.